- Home
- COLA vs ADAP Comparison
COLA vs ADAP Comparison
Compare COLA & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLA
- ADAP
- Stock Information
- Founded
- COLA 2024
- ADAP 2008
- Country
- COLA Singapore
- ADAP United Kingdom
- Employees
- COLA N/A
- ADAP N/A
- Industry
- COLA
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- COLA
- ADAP Health Care
- Exchange
- COLA NYSE
- ADAP Nasdaq
- Market Cap
- COLA 79.8M
- ADAP 71.6M
- IPO Year
- COLA 2025
- ADAP 2015
- Fundamental
- Price
- COLA $10.00
- ADAP $0.24
- Analyst Decision
- COLA
- ADAP Strong Buy
- Analyst Count
- COLA 0
- ADAP 5
- Target Price
- COLA N/A
- ADAP $1.83
- AVG Volume (30 Days)
- COLA 81.5K
- ADAP 2.6M
- Earning Date
- COLA 01-01-0001
- ADAP 05-14-2025
- Dividend Yield
- COLA N/A
- ADAP N/A
- EPS Growth
- COLA N/A
- ADAP N/A
- EPS
- COLA N/A
- ADAP N/A
- Revenue
- COLA N/A
- ADAP $178,032,000.00
- Revenue This Year
- COLA N/A
- ADAP N/A
- Revenue Next Year
- COLA N/A
- ADAP $65.49
- P/E Ratio
- COLA N/A
- ADAP N/A
- Revenue Growth
- COLA N/A
- ADAP 195.34
- 52 Week Low
- COLA $9.95
- ADAP $0.20
- 52 Week High
- COLA $10.05
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- COLA N/A
- ADAP 37.78
- Support Level
- COLA N/A
- ADAP $0.23
- Resistance Level
- COLA N/A
- ADAP $0.26
- Average True Range (ATR)
- COLA 0.00
- ADAP 0.04
- MACD
- COLA 0.00
- ADAP 0.01
- Stochastic Oscillator
- COLA 0.00
- ADAP 31.85
About COLA COLUMBUS ACQUISITION CORP
Columbus Acquisition Corp is a blank check company.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.